The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib

Conroy, Guillaume; Salleron, Julia; Belle, Arthur; Bensenane, Mouni; Nani, Abdelbasset; Ayav, Ahmet; Peiffert, D.; Lopez, Anthony; Baumann, Cédric; Barraud, Hélène; Bronowicki, Jean–Pierre

doi:10.18632/oncotarget.21401

Cited by 25 publications

(29 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As is listed in Table 1 , all articles were published between 2014 and 2017 in English peer-reviewed journals. Among these articles, 16 articles 7 - 12 , 14 , 17 , 20 - 25 , 27 , 28 were from China, 4 articles 13 , 15 , 16 , 19 were from Italy, one was from Korea 18 and another was from France 26 . These articles included a variety of cancers, among them 6 for Hepatocellular carcinoma, 3 for Esophageal squamous cell carcinoma (ESCC), 3 for Gastric Cancer, 3 for colorectal cancer, one for Small Cell Lung Cancer (SCLC), one for Prostate cancer, one for Renal cell cancer, one for Biliary tract cancer, one for Malignant obstructive jaundice, one for non-small cell lung cancer (NSCLC) and one for Acral Melanoma.. As shown in Table 1 , the reference of 7 and 8 were performed in two independent patient populations, they separately had two HRs.…”

Section: Resultsmentioning

confidence: 99%

Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis

Yang¹,

Chang²,

Meng³

et al. 2018

J. Cancer

291

265

View full text Add to dashboard Cite

Systemic immune-inflammation index (SII), on the basis of lymphocyte, neutrophil and platelet counts had been published to be a good prognostic factor in multiple cancers. Nevertheless, the prognostic value of SII in cancer patients remains inconsistent. Therefore, we carried out a meta-analysis to evaluate the prognostic value of SII in these patients with cancer. A total of 22 articles with 7657 patients enrolled in this meta-analysis. The combined result revealed that a high SII was evidently correlated with poor overall survival (OS) (HR=1.69, 95%CI=1.42-2.01, p<0.001), poor time to recurrent (TTR) (HR=1.87, p<0.001) , poor progress-free survival (PFS) (HR=1.61, p=0.012) ,poor cancer-specific survival (CSS) (HR=1.44, p=0.027) , poor relapse-free survival (RFS) (HR=1.66, p=0.025) and poor disease-free survival (DFS) (HR=2.70, p<0.001) in patients with cancers. Subgroup analysis indicated that SII over the cutoff value could predict worse overall survival in Hepatocellular carcinoma (p<0.001), Gastric cancer (p=0.005), Esophageal Squamous Cell Carcinoma (p=0.013), Urinary system cancer (p<0.001), Small cell lung cancer (p<0.001), Non-Small cell lung cancer (p<0.001) and Acral Melanoma (p<0.001). The largest effect size was observed in the Hepatocellular carcinoma (HR=2.11). In addition, these associations did not vary significantly by the cutoff value, sample size and ethnicity. Therefore, high SII may be a potential prognostic marker in patients with various cancers and associated with the poor overall outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis

Yang¹,

Chang²,

Meng³

et al. 2018

J. Cancer

291

265

View full text Add to dashboard Cite

show abstract

“…Eight studies were conducted in Asia, mainly in China and Japan, 8 studies were conducted in America and Europe, and two were multicentered covering locations in western and eastern countries (17,21). Thirteen studies focused on the NLR as prognostic factors, one study analyzed the association between neutrophil count and survival outcome (25), three studies explored the PLR prediction function, one study investigated the prognostic function of the monocyte -to-lymphocyte ratio (MLR) (28) and one the lymphocyte-to-monocyte ratio (LMR) (33), and three studies reported on inflammation biomarkers as risk factors for survival, such as IL-17A, IL8, IL10, Ang-2, G-CSF, HGF, and leptin, etc.…”

Section: Characteristics Of Included Articlesmentioning

confidence: 99%

Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

The purpose of this meta-analysis is to investigate the effectiveness of the prognostic roles of blood inflammatory markers in hepatocellular carcinoma (HCC) patients receiving sorafenib. Methods: We carried out a comprehensive literature search in four databases. Study endpoints, hazard ratios (HRs) and the associated 95% confidence intervals (CI) for clinical outcomes, which were to assess therapeutic efficacy, were extracted. This meta-analysis was conducted by Review Manager 5.3. Results: We summarized the available evidence from 18 studies with a total of 2,745 cases. The pooled results showed that the synthesized HR favored patients with low pretreatment NLR (neutrophil-to-lymphocyte ratio), which also indicated that HCC patients with a lower baseline NLR may have a better response to sorafenib than those with higher NLR (HR = 1.76, 95% CI [1.44, 2.15], P < 0.00001, I² = 68%). Significance was also observed for the prognostic function of the PLR (platelet-to-lymphocyte ratio) of HCC patients treated with sorafenib (HR = 1.49, 95% CI [1.16, 1.93], P = 0.002, I² = 0%, P = 0.65). The subgroup analysis revealed that different gene backgrounds play a prominent role in the source of heterogeneity. Interestingly, the predictive effect on OS (overall survival) was more pronounced as the NLR cutoff value increased. Notably, a significant predictive effect of NLR on the clinical outcome was detected in HCC patients treated with sorafenib compared to those treated with tivantinib. Conclusion: In conclusion, the present study reported promising predictive biomarkers for HCC patients and notably indicated that HCC patients with a lower baseline NLR and PLR may have a better response to sorafenib than those with higher ones. Further large-scale prospective studies are required to determine the optimal NLR and PLR cutoff values, which are important for identifying the dominant populations for sorafenib treatment.

show abstract

“…The detailed selection procedure was presented in Figure . Finally, a total of 26 articles (Absenger et al, ; Chen et al, ; Colloca, Venturino, & Guarneri, ; Conroy et al, ; Cox et al, ; Deng et al, ; Dirican et al, ; Du & Lu, ; Gao et al, ; Grenader et al, ; Grenader et al, ; Hala & Ahmed, ; Inoue et al, ; Jin et al, ; B. S. Lee et al, ; Liu et al, ; Lu et al, ; Neal et al, ; Park et al, ; Song et al, ; Suzuki et al, ; Szkandera et al, ; Wood et al, ; Ying et al, ; Zhou et al, , ) with 13,945 GI tumor patients were enrolled, and these cases were diagnosed with eight different kinds of digestive cancers, including three GI tract tumors, and five malignant neoplasms of the hepatobiliary pancreatic system. All these 26 research were evaluated in 9 different countries, including China (11 studies), UK (5 studies), Austria (2 studies), Japan (2 studies), South Korea (2 studies), Italy (1 study), France (1 study), Egypt (1 study), and Turkey (1 study).…”

Section: Resultsmentioning

confidence: 99%

Prognostic significance of peripheral blood‐derived neutrophil/lymphocyte ratio in patients with digestive cancer

Liu

Luo

Zhu

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Accumulating studies reported the clinical value of derived neutrophil/lymphocyte ratio (dNLR) regarding the prediction of survival outcomes in digestive cancers, however, the prognostic significances of dNLR in these cancers were inconsistent. This study was carried out to clarify the relationship between circulating dNLR and prognosis in gastrointestinal (GI) cancers. Eligible publications were collected and extracted by searching Pubmed, Embase, Web of Science, and Google Scholar up to November 21, 2018. The prognostic impact of dNLR in subjects with GI cancers was assessed with the overall hazard ratios (HRs). A total of 26 studies with up to 13,945 participants were recruited. Our findings showed that peripheral blood dNLR before treatment could be a useful prognostic predictor in digestive cancers, an elevated dNLR indicated a shorter overall survival (OS) in GI tumors (HR, 1.44; 95% confidence interval [CI], 1.36-1.51).Furthermore, its significant prognostic value for OS was also confirmed in subgroup analyses stratified by disease type, publication year, type of research, detection method, geographic location, cut-off value, treatment, analysis type, follow-up time and disease stage. In addition, high dNLR was significantly associated with worse cancer-specific survival (HR, 1.25; 95% CI, 1.04-1.47) and inferior event-free survival (HR, 1.22; 95% CI, 1.11-1.33) in patients with digestive cancers. Our study showed elevated peripheral blood dNLR may indicate unfavorable outcomes in digestive cancer.

show abstract

The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib

Cited by 25 publications

References 51 publications

Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis

Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis

Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis

Prognostic significance of peripheral blood‐derived neutrophil/lymphocyte ratio in patients with digestive cancer

Contact Info

Product

Resources

About